Loading
A phase 1/2 trial of ISM6331 in mesothelioma, run by InSilico Medicine Hong Kong Limited, now recruiting.
Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06566079 by InSilico Medicine Hong Kong Limited, with 160 participants planned, started 2024-12-27 and due to reach its primary completion in 2027-08-31. Interventions recorded: ISM6331.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Insilico Medicine and the tag pipeline.
Shares Mesothelioma and the tag pipeline.
Shares Mesothelioma and the tag pipeline.
Shares Mesothelioma and the tag pipeline.
Shares Mesothelioma and the tag pipeline.
Shares Mesothelioma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/